2024
Survival Among Patients With High-Risk Gastrointestinal Cancers During the COVID-19 Pandemic
Janczewski L, Browner A, Cotler J, Palis B, Chan K, Joung R, Bentrem D, Merkow R, Boffa D, Nelson H. Survival Among Patients With High-Risk Gastrointestinal Cancers During the COVID-19 Pandemic. JAMA Network Open 2024, 7: e240160. PMID: 38441896, PMCID: PMC10915687, DOI: 10.1001/jamanetworkopen.2024.0160.Peer-Reviewed Original ResearchMeSH KeywordsCOVID-19Databases, FactualFemaleGastrointestinal NeoplasmsHumansMalePandemicsRetrospective StudiesConceptsStage IV diseaseRetrospective cohort studyCohort studyQuality care deliveryIV diseaseOperative mortalityHigh riskPandemic-related stressorsAssociated with increased 1-year mortalityDiagnosis of stage IMultivariate logistic regressionCOVID-19 pandemicCare deliveryNational Cancer DatabaseKaplan-Meier curvesEvaluate 30-dayMain OutcomesFollow-up dataCancer communityPrepandemic levelsLogistic regressionCancer DatabaseCOVID-19COVID-19 infectionMalignant neoplasms
2023
Alterations in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US
Janczewski L, Cotler J, Merkow R, Palis B, Nelson H, Mullett T, Boffa D. Alterations in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US. JAMA Network Open 2023, 6: e2340148. PMID: 37902756, PMCID: PMC10616721, DOI: 10.1001/jamanetworkopen.2023.40148.Peer-Reviewed Original ResearchMeSH KeywordsAgedCOVID-19Databases, FactualFemaleHospitals, CommunityHumansMaleMiddle AgedNeoplasmsPandemicsRetrospective StudiesConceptsNational Cancer DatabaseCancer treatmentAcademic hospitalCommunity hospitalMAIN OUTCOMECOVID-19 pandemicProportion of patientsRetrospective cohort studyAvailability of treatmentFirst yearUnderwent surgeryCohort studyMedian ageCancer surgeryMedian timeTreatment of cancerCancer careTreatment modalitiesCancer screeningCancer DatabaseMedian travel distancePatientsHospitalSurgeryCancerRespect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy
Li A, Canavan M, Ermer T, Maduka R, Zhan P, Pichert M, Boffa D, Blasberg J. Respect the Middle Lobe: Perioperative Risk of Bilobectomy Compared With Lobectomy and Pneumonectomy. The Annals Of Thoracic Surgery 2023, 117: 163-171. PMID: 37774762, DOI: 10.1016/j.athoracsur.2023.09.023.Peer-Reviewed Original ResearchMeSH KeywordsBronchiCarcinoma, Non-Small-Cell LungHumansLung NeoplasmsPneumonectomyRetrospective StudiesConceptsLower bilobectomyLeft pneumonectomyLung cancerMiddle lobeRight-sided lung cancerCox proportional hazards modelThirty-day morbidityTotal lung functionPreoperative risk stratificationThoracic Surgeons databaseProportional hazards modelPneumonectomy patientsUpper bilobectomyBronchial involvementPerioperative mortalityPerioperative riskPerioperative variablesPatient demographicsPulmonary resectionRight pneumonectomySecondary outcomesLung functionMiddle lobectomyPrimary outcomePropensity matchingAssociation Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer: Potential for Stage Classification Reform
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Udelsman B, Nemeth A, Boffa D. Association Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer: Potential for Stage Classification Reform. Annals Of Surgical Oncology 2023, 30: 4180-4191. PMID: 36869917, DOI: 10.1245/s10434-023-13287-9.Peer-Reviewed Original ResearchMeSH KeywordsHumansLymphatic MetastasisNeoplasm StagingPrognosisProportional Hazards ModelsRetrospective StudiesStomach NeoplasmsConceptsStage IV gastric cancerNonregional lymph nodesMultivariable Cox modelLymph nodesGastric cancerMetastatic patternCox modelStage IV gastric cancer patientsBetter median survivalNational Cancer DatabaseRetrospective cohort studyStage IV patientsKaplan-Meier curvesGastric cancer patientsPropensity score-matched sampleSingle organYears of ageDistant diseaseCohort studyIV patientsMedian survivalMetastatic diseaseMost patientsBetter prognosisSystemic organs
2022
Thoracic CT follow-up after non-small-cell lung cancer resection
Woodard G, Boffa D, Blasberg J. Thoracic CT follow-up after non-small-cell lung cancer resection. The Lancet Oncology 2022, 23: e484. PMID: 36328013, DOI: 10.1016/s1470-2045(22)00618-0.Commentaries, Editorials and LettersAssociation of Lymph Node Sampling and Clinical Volume in Lobectomy for Non–Small Cell Lung Cancer
Udelsman BV, Chang DC, Boffa DJ, Gaissert HA. Association of Lymph Node Sampling and Clinical Volume in Lobectomy for Non–Small Cell Lung Cancer. The Annals Of Thoracic Surgery 2022, 115: 166-173. PMID: 35752354, DOI: 10.1016/j.athoracsur.2022.05.051.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerHigh-volume centersThoracic Surgeons General Thoracic Surgery DatabaseGeneral Thoracic Surgery DatabaseMedium-volume centersLow-volume centersCell lung cancerThoracic Surgery DatabaseNodal harvestParticipant centersLymph nodesLung cancerSurgery DatabaseLymph node samplingMultivariable logistic regressionHigher center volumeLong-term survivalPotential quality metricElective lobectomyAdjuvant therapyNodal yieldGuideline adherencePrimary outcomeUnivariable analysisMultivariable analysisAppendiceal Cancer in the National Cancer Database: Increasing Frequency, Decreasing Age, and Shifting Histology.
Salazar MC, Canavan ME, Chilakamarry S, Boffa DJ, Schuster KM. Appendiceal Cancer in the National Cancer Database: Increasing Frequency, Decreasing Age, and Shifting Histology. Journal Of The American College Of Surgeons 2022, 234: 1082-1089. PMID: 35703801, DOI: 10.1097/xcs.0000000000000172.Peer-Reviewed Original ResearchMeSH KeywordsAdultAppendectomyAppendiceal NeoplasmsAppendicitisCarcinoid TumorColonic NeoplasmsHumansMiddle AgedRetrospective StudiesConceptsRight-sided colon cancerNational Cancer DatabaseAppendiceal cancerColon cancerAcute appendicitisNonoperative managementCancer DatabasePatients 49 yearsPatients 18 yearsArea of residenceLogistic regression modelsAppendiceal histologyPatients 40Appendectomy specimensPatient ageCarcinoid tumorsAppendiceal carcinoidsCancer incidenceCancer histologySmall studyAge groupsCancerCarcinoidsLogistic regressionHistology
2021
Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment Initiation
Frosch ZAK, Illenberger N, Mitra N, Boffa DJ, Facktor MA, Nelson H, Palis BE, Bekelman JE, Shulman LN, Takvorian SU. Trends in Patient Volume by Hospital Type and the Association of These Trends With Time to Cancer Treatment Initiation. JAMA Network Open 2021, 4: e2115675. PMID: 34241630, PMCID: PMC8271360, DOI: 10.1001/jamanetworkopen.2021.15675.Peer-Reviewed Original ResearchConceptsTreatment initiationCross-sectional studyCommunity hospitalHospital typeAcademic centersPatient volumeNCI centersMAIN OUTCOMETimely treatmentMean annual rateCancer treatmentCancer treatment initiationCancer-accredited hospitalsCommon incident cancerFirst cancer treatmentNational Cancer DatabaseTime interaction termNational Cancer InstituteMean annual changeAdult patientsIncident cancerReferral centerTreatment delayCancer careCancer Database
2020
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features
Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncology 2020, 6: 1741-1750. PMID: 32940636, PMCID: PMC7499246, DOI: 10.1001/jamaoncol.2020.4232.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCohort StudiesFemaleHumansLung NeoplasmsNeoplasm StagingRetrospective StudiesConceptsNode-negative non-small cell lung cancerHigh-risk pathologic featuresNon-small cell lung cancerAdjuvant chemotherapyCell lung cancerPathologic featuresTumor sizeSurvival benefitCohort studyLung cancerNode-negative NSCLCEarly-stage non-small cell lung cancerCox proportional hazards regression modelHigh-risk clinicopathologic featuresProportional hazards regression modelsNational Cancer DatabaseRetrospective cohort studyTreatment-naive patientsAdjuvant chemotherapy useHigh-risk featuresAssociation of survivalHazards regression modelsImmortal time biasChemotherapy useEligible patientsIntestinal metaplasia around the gastroesophageal junction is frequently associated with antral reactive gastropathy: implications for carcinoma at the gastroesophageal junction
Vyas M, Celli R, Singh M, Patel N, Aslanian HR, Boffa D, Deng Y, Ciarleglio MM, Laine L, Jain D. Intestinal metaplasia around the gastroesophageal junction is frequently associated with antral reactive gastropathy: implications for carcinoma at the gastroesophageal junction. Human Pathology 2020, 105: 67-73. PMID: 32941964, PMCID: PMC11152084, DOI: 10.1016/j.humpath.2020.08.007.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsBile refluxIntestinal metaplasiaReactive gastropathyGEJ regionMucosal injuryMucosal changesGastroesophageal junctionAntral intestinal metaplasiaDistal esophageal adenocarcinomaDetailed clinical historySex-matched patientsGastric antral biopsiesAnti-inflammatory drugsGastric bile refluxMucosal inflammationProximal stomachDistal esophagusMedication usePancreatic metaplasiaPathology databaseProximal gastricAntral biopsiesClinical historyGastric biopsiesWhere the Other Half Dies: Analysis of Mortalities Occurring More Than 30 Days After Complex Cancer Surgery
Resio BJ, Gonsalves L, Canavan M, Mueller L, Phillips C, Sathe T, Swett K, Boffa DJ. Where the Other Half Dies: Analysis of Mortalities Occurring More Than 30 Days After Complex Cancer Surgery. Annals Of Surgical Oncology 2020, 28: 1278-1286. PMID: 32885398, DOI: 10.1245/s10434-020-09080-7.Peer-Reviewed Original ResearchMeSH KeywordsAgedConnecticutHumansMedicareNeoplasmsPatient DischargePatient ReadmissionRegistriesRetrospective StudiesSEER ProgramUnited StatesConceptsComplex cancer surgeryCause of deathCancer surgeryLate mortalityNursing facilitiesTumor registry databaseLate postoperative periodDay of surgeryLocation of deathAnalysis of mortalityCircumstances of deathIndex admissionPulmonary causesCardiac causesOperative mortalityFatal complicationPostoperative periodThromboembolic diseaseNonmetastatic cancerRegistry databaseDeath documentationSurgical safetySurgeryPatientsMortalityAssociation of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer
Leapman MS, Presley CJ, Zhu W, Soulos PR, Adelson KB, Miksad RA, Boffa DJ, Gross CP. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open 2020, 3: e207205. PMID: 32511721, PMCID: PMC7280954, DOI: 10.1001/jamanetworkopen.2020.7205.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerFirst-line ICI treatmentImmune checkpoint inhibitorsPD-L1 expressionPD-L1 testingNegative PD-L1 expressionHigh PD-L1 expressionCell lung cancerICI treatmentCheckpoint inhibitorsLung cancerDeath ligand 1 (PD-L1) expression statusElectronic health record-derived databaseFirst-line immune checkpoint inhibitorsCell death ligand 1 (PD-L1) expressionExpression statusLow PD-L1 expressionPD-L1 expression statusDeath ligand 1 (PD-L1) expressionRetrospective cohort studyFirst-line treatmentLigand 1 expressionProportion of patientsReal-world care
2019
Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma
Kurbatov V, Balayev A, Saffarzadeh A, Heller DR, Boffa DJ, Blasberg JD, Lu J, Khan SA. Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma. The Annals Of Thoracic Surgery 2019, 109: 343-349. PMID: 31568747, DOI: 10.1016/j.athoracsur.2019.08.050.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma of LungAdultAgedCohort StudiesDatabases, FactualDisease-Free SurvivalFemaleHumansImmunotherapyKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentSurvival AnalysisTumor MicroenvironmentConceptsTumor immune microenvironmentImmune microenvironmentLung adenocarcinomaOverall survivalRisk groupsMast cellsCox proportional hazard modelingEarly-stage lung adenocarcinomaLow-risk subtypesKaplan-Meier analysisPathological staging systemProportional hazard modelingImproved clinical outcomesCancer immune microenvironmentImmune cell typesEarly lung adenocarcinomaActivation stateClinical outcomesValidation cohortMacrophage contentStaging systemMultivariable modelCIBERSORT analysisPatientsClinical decisionComparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer
Uhlig J, Case MD, Blasberg JD, Boffa DJ, Chiang A, Gettinger SN, Kim HS. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non–Small Cell Lung Cancer. JAMA Network Open 2019, 2: e199702. PMID: 31433481, PMCID: PMC6707019, DOI: 10.1001/jamanetworkopen.2019.9702.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdolescentAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantComparative Effectiveness ResearchDatabases, FactualFemaleFollow-Up StudiesHumansLung NeoplasmsMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPneumonectomyProportional Hazards ModelsRadiotherapy, AdjuvantRetrospective StudiesSurvival RateTreatment OutcomeYoung AdultConceptsStage IV non-small cell lung cancerNon-small cell lung cancerPrimary tumor siteSuperior overall survivalSystemic therapySurgical resectionCell lung cancerExternal beam radiotherapyOverall survivalSurvival benefitLocal treatmentTumor siteTumor characteristicsLung cancerTreatment groupsMultivariable Cox proportional hazards regression modelsOligometastatic non-small cell lung cancerStage IV squamous cell carcinomaSurvival rateCox proportional hazards regression modelProportional hazards regression modelsComparative effectiveness research studyCancer-specific factorsNational Cancer DatabaseStage IV disease
2016
Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall
Gao SJ, Corso CD, Blasberg JD, Detterbeck FC, Boffa DJ, Decker RH, Kim AW. Role of Adjuvant Therapy for Node-Negative Lung Cancer Invading the Chest Wall. Clinical Lung Cancer 2016, 18: 169-177.e4. PMID: 27890561, DOI: 10.1016/j.cllc.2016.08.005.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdjuvant chemotherapyAdjuvant chemoradiation therapyUnderwent surgeryChemoradiation therapyChest wall resectionRadiation therapyMargin statusTumor sizeLung cancerWall resectionNode-negative lung cancerNational Cancer Data BaseCox proportional hazards modelMargin-positive patientsChest wall invasionCell lung cancerLog-rank testStage IIB tumorsProportional hazards modelAdjuvant therapyAdjuvant treatmentOverall survivalMultivariable analysisIIB tumorsThe differential impact of preoperative comorbidity on perioperative outcomes following thoracoscopic and open lobectomies
Jawitz OK, Wang Z, Boffa DJ, Detterbeck FC, Blasberg JD, Kim AW. The differential impact of preoperative comorbidity on perioperative outcomes following thoracoscopic and open lobectomies. European Journal Of Cardio-Thoracic Surgery 2016, 51: 169-174. PMID: 27458143, DOI: 10.1093/ejcts/ezw239.Peer-Reviewed Original ResearchConceptsNationwide Inpatient SampleOpen lobectomyPostoperative lengthVATS lobectomyLobectomy patientsVideo-assisted thoracoscopic surgery lobectomyBenign lung conditionsOpen lobectomy patientsPerioperative pulmonary complicationsVATS lobectomy patientsNumber of comorbiditiesNon-elective admissionsCell lung cancerMultivariable logistic regressionThoracoscopic surgery lobectomyStandard of careUtilization Project databasePreoperative patient comorbiditiesCumulative incidence modelsLogistic regression modellingHospital mortalityPreoperative comorbiditiesPulmonary complicationsGreater comorbidityPerioperative outcomes